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ABSTRACT: Relative stability of therapeutic antibody candidates is currently evaluated primarily through their response to thermal
degradation, yet this technique is not always predictive of stability in manufacture, shipping, and storage. A rotating disk shear device is
proposed that produces defined shear conditions at a known solid–liquid interface to measure stability in this environment. Five variants
of IgG1 and IgG4 antibodies were created using combinations of two discrete triple amino acid sequence mutations denoted TM and
YTE. Antibodies were ranked for stability based on shear device output (protein decay coefficient, PDC), and compared with accelerated
thermal stability data and the melting temperature of the CH2 domain (Tm1) from differential scanning calorimetry to investigate technique
complimentarity. Results suggest that the techniques are orthogonal, with thermal methods based on intramolecular interaction and
shear device stability based on localized unfolding revealing less stable regions that drive aggregation. Molecular modeling shows the
modifications’ effects on the antibody structures and indicates a possible role for Fc conformation and Fab-Fc docking in determining
suspended protein stability. The data introduce the PDC value as an orthogonal stability indicator, complementary to traditional thermal
methods, allowing lead antibody selection based on a more full understanding of process stability. C© 2013 The Authors. Journal of
Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:437–444, 2014
Keywords: protein aggregation; protein structure; molecular modeling; IgG antibody; thermal analysis; biopharmaceuticals characteriza-
tion; calorimetry (DSC); in silico modeling
INTRODUCTION
Minimizing aggregation in protein therapeutics is a major
challenge in drug development, involving a thorough under-
standing of the factors influencing protein stability over the
product lifetime.1,2 Aggregation is a critical regulatory concern
when choosing a lead candidate for production because of the
health risks associated with injecting aggregated proteins into
patients,3,4 and their ability to neutralize antibodies and in-
hibit the efficacy of the product.5 Current guidelines advise
measuring aggregation using the light obscuration method de-
scribed in the European Pharmacopoeia methods 2.9.196 and
the US Pharmacopoeia (USP) <788>.7 These state that partic-
ulates greater than 10 :m in size should be controlled at or be-
low 6000 particles per container, whereas particulates greater
than 25 :m should be controlled at less than 600 particles per
container.8
One common approach to mitigate particulate formation and
other degradation phenomena is to determine relative stability
with the aid of temperature hold studies, often after screen-
ing many candidates using differential scanning calorimetry
(DSC).9 Other methods for looking at the stability of candi-
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dates, which rely on structural characterization are available
such as circular dichroism10 and spectroscopy techniques.11,12
These methods give more specific information about the can-
didates but cannot easily be used to rank antibody stabilities.
Alternative methods are emerging that measure protein stabil-
ity based on degradation by interfacial effects. These methods
allow assessment of the impact of solid–liquid13 or air–liquid14
interfaces at the same time as ranking protein stability in for-
mulation conditions. At present, however, there is little stan-
dardization of such methods and no consensus on which is the
best to use.
Significant amounts of aggregates can form around nuclei
over timeframes relevant to modern pharmaceuticals and un-
der the stress conditions they are exposed to.15,16 Stress is
commonly used as a generic term unless specifically stated
to describe a range of forces (e.g., hydrodynamic, chemical,
thermal, and interfacial) exerted on a protein in different
environments.16–18 For example, one study showed that the ag-
gregate produced was dependent upon whether the solution en-
vironment was shaken or stirred.15,19 These external stresses
can directly disrupt the native conformation of the protein
molecule, causing changes to the surface charge and hydropho-
bicity of the molecule,20 allowing binding to other proteins.21 In
general, the maximum shear rate created during downstream
processing is around 20,000 s−1.22 Such mechanical stress is
generated by pumping, filtration, mixing, fill-finishing, ship-
ping or shaking,23 affecting protein stability,24 and resulting in
a loss of soluble protein.25
The effect of shear stress on the aggregation rate of pro-
teins has produced conflicting reports seemingly because of the
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presence or absence of different interfaces. There are some sug-
gestions that shear causes minor conformational changes to the
native structure of the monomer.26 Monomeric mAb showed
no aggregation after 30–51 ms exposure to shear rates up to
250,000 s−1, with only reversible aggregates in the 40–60 unit
range observed after 300 s at 20,000 s−1 shear. A second sam-
ple with an aggregate population of 17% was not significantly
altered by the shear rate.22 Although shear alone appears not
to cause formation of large aggregates during mixing and ad-
sorption to stainless steel surfaces shows only small levels of
aggregation,27 together the effects of these forces can more be
pronounced. Previous work highlights how at solid–liquid in-
terfaces both the physiochemical properties of the solid inter-
face and the shear above that boundary directly impact the
rate of antibody aggregate formation.28 This infers the hydrody-
namic environment directly above the surface is critical to rate
of aggregate formation. The rotating disk surface adsorption
shear device used in this work was developed at UCL to mimic
loss of protein to aggregation experienced through solid–liquid
interfacial effects particularly during fill-finish operations.13
Monomer loss from prolonged operation of the device follows
first-order exponential decay and is protein specific, dependent
on both disk speed and surface material.28 By having a well-
controlled shear and interface environment and using the co-
efficient of decay of nine sample points over 2 h of shear de-
vice operation, reproducible results can be achieved using this
method.
The most prominent class of biopharmaceuticals are IgG an-
tibodies, which are globular plasma glycoproteins with a mass
of approximately 146 kDa29 consisting of two light and two
heavy chains, folded to form domains of two beta sheets that
create a sandwich shape held together by conserved disulfide
bonds and other noncovalent interactions. The two identical (
heavy chains contain around 450 amino acids and consist of
three constant and one variable domain. The light chains con-
tain around 215 amino acids and again consist of a constant
and a variable domain. These variable domains are the ori-
gin of protein specificity.30 The IgG4 subtype structure differs
from the IgG1 subtype in that they are unable to cross-link two
antigens because of the monovalent behavior.31 It has been sug-
gested this behavior is because of an amino acid change from
proline to serine in the core of the hinge of IgG132 resulting
in less disulfide bond formation. The molecule dissociates from
the hinge and produces identical monomeric halves, each con-
taining a light and heavy chain. Bispecificity is observed when
two different IgG4 monomeric halves reform to give a whole
biclonal antibody. This prevents precipitation of the purified
antibodies33 under normal conditions because they are unable
to cross-link two antigens.
Considerable work has gone into defining the role of the
hinge on the effector functions of an antibody. For IgG, this
hinge can generally be divided into upper, middle, and lower
regions. The middle hinge stretches from the first to the last
cysteine that form disulfide bridges and is believed to be rigid
because of interheavy chain disulfide bridging and the subse-
quent formation of polyproline helices.34 It is considered that
the hinge region acts as a spacer, effecting segmental flexi-
bility and allowing the Fab arms to move in relation to the
Fc.35 A study showed that changes in the amino acid sequences
could affect the rigidity of the hinge, which in turn affected
the effector function of the antibody.36 Further studies show
that IgG4 has less flexibility in the hinge region than IgG1,37
Figure 1. Diagram representing comparability of thermal degrada-
tion and interfacial shear-induced aggregation for determining relative
stability. The thermal degradation route is based on work on nonnative
protein aggregation by Roberts and co-workers,41,42 whereas the inter-
facial route builds upon this background with work by Biddlecombe
et al.28
which correlates with a reduction in stability between the two
subgroups.37,38 This also correlates with a greater hydrody-
namic radius of the IgG4 subtype.
In this study, the effects of controlled antibody modifications
TM39 and YTE40 on a drug candidate’s secondary and tertiary
structures and overall charge were evaluated. By using the
solid–liquid interfacial shear device, the relative stability of
protein candidates was measured. This technique was com-
pared with melting temperature (Tm) data from DSC and the
results from a 4-week accelerated stability study at 40◦C to
give relative stability based on thermal parameters. This com-
parison could be used to determine whether the shear device
method could be used as an orthogonal method for lead anti-
body screening (Fig. 1).
Molecular modeling techniques43 were then employed to help
determine the effect of the modifications on the proteins’ sec-
ondary and tertiary structures, to help explain any trends seen
in the relative stabilities of the antibodies using surface charge
and spatial aggregation propensity (SAP) information.
MATERIALS AND METHODS
Antibodies
Five sets of human monoclonal antibodies, three IgG1 and two
different IgG4, were expressed by CHO cells and purified using
protein A and cation chromatography at MedImmune (Cam-
bridge, UK). Candidates were formulated in a stability buffer
containing L-histidine and D(+)-trehalose pH 5.5 at concentra-
tions of 1 mg/mL, and with an overall purity of at least 99%.
Antibodies were labeled as IgG1—WT, YTE, and TM YTE—and
IgG4—WT and YTE.
Size-Exclusion High-Pressure Liquid Chromatography
A TSKgel3000SWXL (TOSOH Biosciences, Tokyo, Japan) size-
exclusion column (7.8 × 300 mm2) was run using an Agilent
1100 HPLC system (California) comprising degasser, solvent
pump, injector, temperature controller, and a fixed-wavelength
(DAD) UV detector. The mobile phase was 200 mM sodium
phosphate buffer pH 7.4 used at a flow rate of 1 mL/min. Sam-
ples were centrifuged at 18,000 g for 10 min prior to size-
exclusion high-pressure liquid chromatography (SE-HPLC).
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Injection volume for samples was set at 20 :L and the eluate
from the column was monitored at 280 nm. Peaks were subse-
quently integrated and antibody monomer concentration was
calculated as a proportion of the peak area prior to exposure
to the stress of the shear device, taking into account dilution
effects from the displacement-based sampling method of the
custom made shear device.
Shear Device
The shear device generated a defined high-shear environment
used to simulate the effect of surface adsorption and shear
forces encountered during processing. The round device cham-
ber was constructed of stainless steel (30 × 17 mm2) contain-
ing a stainless steel disk (26 × 8 mm2). It applied high-shear
rates while eliminating the air–liquid interface and controlling
temperature.13
Shear Device Operation
The shear device was filled with 7 mL of antibody solution
from a syringe through a one-way valve on the top face and all
air was excluded. The temperature was controlled at 17◦C by
circulation of water at predetermined temperatures with a fixed
flow rate controlled by a peristaltic pump (Beckman Coulter,
Brae, California) feeding into the cooling jacket. The antibodies
were sheared using a 240-grit stainless steel disk at 6000, 7500,
9000, and 12,000 rpm equivalent to a maximum shear strain
rate of 1.59, 1.98, 2.38, and 3.17 × 104 s−1, respectively, for 2 h.
Samples (100 :L) were taken every 15 min by displacing the
sample chamber contents using the L-histidine stability buffer.
Each sample resulted in a 1.4% dilution of the chamber solution
with a final dilution over 2 h of around 10%. This dilution factor
was subsequently accounted for in calculations.
Differential Scanning Calorimetry
Differential scanning calorimetry studies were performed us-
ing a Microcal VP-Capillary DSC (GE Healthcare, Bucks, UK).
Samples were prepared in the stability buffer at concentrations
of 1 mg/mL. The change in the heat capacity of the sample was
measured in comparison with a sample of buffer alone as sam-
ples were heated from 45◦C to 95◦C at a rate of 60◦C/h. The heat
capacity data were normalized and corrected for the baseline.
Accelerated Stability Studies
Antibodies were held in stability buffer at 10 mg/mL at a tem-
perature of 40◦C. Samples were analyzed at 0, 2, and 4 weeks
from the start of the experiment using HPLC and the monomer
percentage determined.
Molecular Modeling
Modeling and analysis of the IgG Fc was performed using Py-
Mol (Schrodinger, Munich, Germany) and Discovery Studios
(Accelyrys, California) software.
RESULTS AND DISCUSSION
Shear Stability of mAb Candidates: A Divide Between IgG1
and IgG4
The candidates for stability studies were produced from the
IgG1 and IgG4 formats of an antibody. These formats were mod-
ified using combinations of two discrete, defined triple amino
acid sequence mutations, TM39 and YTE,40 to give five variants
Figure 2. Diagram showing the site of each mutation on the structure
of the antibody and the resultant antibody formats used for comparison.
3D protein structure taken from PDB, filename 2DQT.
with known pharmacological properties (Fig. 2). The five dif-
ferent antibodies were processed in the shear device at 6000,
7500, 9000, and 12,000 rpm. The antibody concentration se-
lected was 1 mg/mL based on previous work and experimental
evidence showing little change in the protein decay coefficient
(PDC) between 0.5 and 10 mg/mL and a desire to minimize
sample consumption. Each processed sample was cloudy when
removed from the chamber, indicating the presence of aggre-
gate. The insoluble material was removed by centrifugation
prior to SE-HPLC. The area under the monomer curve at 15
min intervals was fitted to an exponential decay curve:
C(t) = C0e−kt
where C(t) is the monomer concentration (mg/mL) at time t
(h), C0 is the monomer concentration at time zero and k is the
PDC (h−1). Statistical t-tests performed on the groups of results
from each shear rate gave a confidence level of 97.5% that the
trend seen was significant. The monomer reduction profiles for
IgG1 TM YTE (Fig. 3) are shown as an example of the profiles
seen. Greater monomer loss occurred at increased disk speeds
indicating that the stability of the antibody was affected by
processing at a range of disk speeds in the device.
The PDC values for different disk speeds were used to com-
pare monomer losses between each run. These were fitted to a
second-order regression to highlight clear trends that showed
the antibodies to have varying levels of sensitivity to increases
in the disk speed (Table 1), caused by their different inher-
ent stabilities in these conditions. Overall, the IgG1 subtype
candidates had a lower monomer loss than the IgG4s at any
given disk speed. There was however more variability between
mutants in the IgG1 PDC values at each disk speed, with the
IgG4 candidates showing similar, high PDC values, possibly
indicating their interfacial shear stability is already compro-
mised. This is likely related to the lack of a stable hinge region
holding the antibody halves together.32 Two distinct lots of the
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Figure 3. The effect of disk speed on perceived monomer loss in shear
device. Percentage of original monomer concentration remaining over
time of shear for 1 mL/mg sample of IgG1 TM YTE in L-histidine and
D(+)-trehalose buffer in shear device at 6000, 7500, 9000, and 12 000
rpm. Error bars show the standard error of the sets for their fit with
the regression line.
Table 1. Protein Decay Coefficient Values at Different Disk Speeds
for All Candidates
Protein Decay Coefficient (h−1)
Antibody 6000 7500 9000 12,000
IgG1 WT 0.095 0.136 0.179 0.285
IgG1 YTE 0.077 0.108 0.115 0.223
IgG1 TM YTE 0.102 0.163 0.272 0.420
IgG4 WT 0.147 0.209 0.285 0.476
IgG4 YTE 1 0.168 0.212 0.298 0.471
IgG4 YTE 2 0.184 0.219 0.305 0.470
PDC is the coefficient of exponential decay for monomer loss curve of antibod-
ies prepared at 1 mg/mL in L-histidine and D(+)-trehalose buffer after 2 h of shear
device operation. IgG4 YTE duplicates shown for the measure of reproducibility
of technique.
IgG4 YTE were separately produced and purified to test the re-
producibility of the interfacial shear device result. The results
showed that the error of the PDC-derived decreases with disk
speed, creating a need to compromise between ensuring repro-
ducibility of data without losing sensitivity of the technique. A
disk speed of 9000 rpm was chosen to be the optimum level.
The increase in soluble monomer loss with disk speed could
be because of an increase in its loss to aggregate nuclei in solu-
tion or to an increase in the rate of the dissociation of aggregate
precursors from the disk surface, resulting in an increased rate
of aggregation. The work also supported previous observations
that an increase in large aggregates (based on the increased
opalescence of the solution) did not serve to increase the rate
of monomer loss.13 The relatively steady rate of monomer loss
differs from some reported routes of protein aggregation where
the level of monomer loss seems to be low for a nucleation phase,
followed by rapid fibrillation,44,45 indicating the presence of dif-
ferent mechanisms of aggregation.
DSC of mAb Candidates: The IgG1 Subtype Displays Greater
Thermo-Stability than the IgG4 Subtype
The DSC profiles (Fig. 4) showed the antibodies have two clearly
resolved transitions, each peak in the trace giving a Tm value for
Figure 4. The effect of modifications on thermal stability determined
by DSC. DSC profiles to show heat capacity of 1 mg/mL samples of
IgG1 WT, YTE, TM YTE and IgG4 WT and YTE in L-histidine and
D(+)-trehalose buffer (pH 5.5).
the unfolding of each protein domain. The first peak (Tm1) rep-
resenting the unfolding transition of the CH2 domain was well
resolved for most of the antibody candidates. The Fab and CH3
were unresolved in the second unfolding transition (Tm2) with a
higher enthalpy than in Tm1, possibly indicating stronger inter-
actions between subdomains in this region.46 As expected, the
modifications in the CH2 change the Tm1 value significantly.
The Tm1 values for the antibody variants showed a greater
range than the Tm2 values giving different resolutions of the
peaks. Some previous work intimates that peak resolution is re-
lated to the level of interdomain interaction in the antibody,47,48
suggesting that the closer and less resolved the two peaks ap-
pear, the more interaction they have with each other during
unfolding. Other sources however dispute this and state that
the individual domain peaks unfold independently49 and just
happen to overlap because of similar unfolding temperatures.
IgG1 WT displayed the least resolution of the subtype, with
closely associated peaks with a high Tm1 value. IgG1 YTE and
TM YTE had similar profiles with two distinct individual peaks,
but IgG1 TM YTE had a lower Tm1 value. It is interesting
to note that IgG4 WT also had a near identical Tm2 value to
IgG4 YTE. The Tm1 value for IgG4 WT was much higher than
for IgG4 YTE, giving less resolution between the peaks. The
emerging shoulder on the right of Tm2 unfolding transition
for the IgG1 subtype compared with the trailing edge on the
corresponding transition for the IgG4 subtype showed greater
stability in the CH3 region of the IgG1. It is speculated that
greater areas of the peaks could be a result of IgG4’s ability to
rotate and translate more than the IgG1 because of the IgG4’s
aforementioned weaker linker hinge in the Fc.
The Tm1 value is predominantly used in the industry as an
approximation to screen the relative stability of antibodies and
to determine the optimal temperature to perform accelerated
stability testing,50 although the use of this over Tm2 is being
increasingly challenged. The comparison of Tm1 values with
the PDC comparator obtained from the interfacial shear device
monomer loss data would show how related the two stability
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Figure 5. The effect of modifications on accelerated stability studies.
Monomer percentage determined by SE-HPLC at 0, 2, and 4 weeks
using 10 mg/mL antibody samples in L-histidine and trehalose buffer
held at 40◦C.
readings are. On the basis of the greater enthalpy, the Tm2
value should represent the major unfolding transition of the
molecules. It has also been reported that although changes to
the protein structure at Tm1 values are reversible, changes that
occur at Tm2 values are irreversible.41 This could mean that the
Tm2 value is in fact more pertinent to predicting protein ag-
gregation; however, the data showed negligible difference with
Tm2 readings for the modifications, although the IgG1 and IgG4
populations did fall into two distinct subsets. It is logical that
the modifications located in the CH2 region would not greatly
affect the stability of the Fab transition. The weak linker region
in IgG4 molecules could account for the lower stability seen in
general for the IgG4 candidates. This region has reduced in-
terheavy chain disulfide bridge stability, allowing the molecule
to detach into two monomeric halves.32 The resistance of the
whole molecule to degradation must be greater than the sum
of the two halves. It should be stated that the stability of these
molecules is not necessarily related to their efficacy.
Accelerated Thermal Stability of mAb Candidates: IgG4
Candidates Show Reduced Thermal Stability
The accelerated stability results did differentiate between the
IgG1 and IgG4 candidates (Fig. 5). In line with the previ-
ous reports,51 there were minimal amounts of fragmentation
present in the thermally denatured samples, with the vast
majority of monomer loss through aggregation mechanisms.
Curves for loss were fitted to a second-order polynomial curve,
showing a clear trend for each antibody. IgG4 candidates
showed reduced thermal stability in comparison with IgG1 can-
didates. Because the trends reported did not converge, the value
of the monomer percentage at week 4 was used for further anal-
ysis of the data.
Comparison of Shear Device and Thermal Stability: Interfacial
Shear Device Promotes Formation of High-Molecular-Weight
Aggregates
HPLC traces from samples aggregated through the interfa-
cial shear device were compared with those that had been
degraded through thermal routes (Fig. 6). Interfacial shear-
device-degraded samples showed a reduction of monomer and
Figure 6. Comparison of HPLC traces for 5 mg/mL IgG1 WT samples
processed at different conditions. (a) Before processing, (b) —– after
24 h hold at pH 4 and 40◦C, (c) after 60 min shear at 9000 rpm.
no measurable increase in fragments or multimers. This indi-
cates that the antibody had aggregated and formed much larger
particles that had begun to fall out of solution, as shown by the
increased opaqueness of samples taken from the device. This
implies that the multimers are either very short lived, making
them difficult to detect, or they are formed at the solid–liquid
interface prior to release into the bulk solution. Thermally de-
natured samples showed a reduction of monomer, with the ma-
jority of the antibody found as low-molecular-weight multimer,
suggesting a more classically observed nucleation mechanism
for the aggregation.15
The Relationship Between PDC, DSC, and Accelerated Stability:
Values Look at Different Aspects of Stability
The correlation of the thermal stability measured by DSC with
conformational stability measured by adsorption to solid sur-
faces in a high-shear environment was assessed. Different an-
tibodies are shown (Fig. 7a) in terms of their first melting tem-
perature, Tm1, which represents unfolding of the CH2 region.
This comparator is predominantly used in industrial screening
of antibody candidates to determine the most stable candidates
for accelerated stability studies. Comparison of the two stabil-
ity indicators showed that there was no correlation between the
thermal and the surface adsorption-based stability. The IgG4
candidates did show that although they were the least stable
in the shear device, they had relatively good thermal stability
for this transition. The lack of correlation suggests that differ-
ent mechanisms of degradation are involved in the two testing
methodologies.
Comparison of PDC using 1 mg/mL protein with monomer
percentage determined from accelerated stability studies at
40◦C (Fig. 7b) using 10 mg/mL protein revealed little trend
between the two stability indices. The concentrations of anti-
body solution were kept at the standard operating conditions
of each method. The IgG4 accelerated stability data supported
the Tm2 results from the DSC analysis, highlighting the inabil-
ity of the Tm1 values to differentiate between IgG1 and IgG4.
IgG1 YTE was shown to be significantly more stable to damage
via interfacial effects than IgG1 WT, yet slightly less thermally
stable. This indicates that the two methods are not directly
comparable.
A comparison of the Tm1 value and the accelerated stability
method also shows no correlation. Similar to the comparison
of the shear device with Tm1, the Tm1 shows IgG4 candidates
to be comparatively stable, whereas the accelerated stability
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Figure 7. (a) Comparison of PDC with Tm1 for all candidates at a
disk rate of 9000 rpm. y-Axis error bars are for standard error of PDC
fit, and x-axis error bars are for internal error of DSC. (b) Comparison
of monomer remaining at week 4 in accelerated stability results, de-
termined by SE-HPLC and the PDC as determined with custom shear
device method for all candidates at a disk rate of 9000 rpm. x-Axis error
bars are for standard error of PDC fit.
method indicates them to be significantly less stable than the
IgG1. Looking across these comparisons, the three methods
rank stability differently based on distinct mechanisms of loss
of structural integrity.
Insights Based on Molecular Modeling
Molecular models of the IgG1 Fc and hinge region, with two
internal fucosylations, were analyzed for their SAP and elec-
trostatic surface charge displayed in Figure 8. There are known
docking postures of the Fab onto the hinge and the superior sur-
face of the Fc. The CH1-1 loop of the Fab is more intrinsically
disordered than even vhCDR352 and is oriented toward the cen-
tral hinge in the full-length mAb crystal structure,53 though it
does not have electron density in the model 1HZH (PDB). This,
together with high sequence variability in this loop, would im-
ply that it has no conserved interactions with the hinge region.
The minor hinge, however, has greater sequence conservation
and is shown in a stably docked posture in the full-length anti-
body crystal structure,53 orientated with the minor hinge of the
light chain forming an interface with the location of the first
two mutants of the “TM”.
The model results of the three modifications show there is
no significant difference shown in the electrostatic results, with
the overall surface charges of the proteins remaining the same.
This shows that the difference in stability is not from electro-
Figure 8. Comparison of SAP and surface charge of IgG1 WT Fc with
the YTE and TM YTE modified IgG1 Fc’s. Site 1 is the site of the Tm
modification, and site 2 is the site of the YTE modification. Numerical
value of the SAP of site 1 is shown.
static interactions, a key component of colloidal stability. The
SAP models do however show a very noticeable difference in
the hydrophobicity of the hinge region of the Fc with the rest
of the molecule not showing any significant differences. The
increase in the hinge SAP scores shown in Figure 8 correlates
with a reduction in the PDC (improved stability), suggesting
this is the area of the molecule responsible for the change in
stability documented in this instance. It is postulated that hav-
ing a more hydrophilic upper hinge would reduce the range of
motion of the Fab in respect to the Fc, giving a more rigid an-
tibody structure that is less able to fold in on itself to conserve
hydrophobic sections on the Fc. In the case of the YTE, this
allows the enhanced binding to the Neonatal Fc Receptor, but
also seems to allow easier degradation through adsorption at
solid–liquid interfaces. It is suggested that the mobility of the
hinge region is very important to not only in exposing effector
functions of the Fc,36 but also in keeping the antibody stable in
solution.
CONCLUSIONS
The systematic use of known monoclonal antibody variants
of IgG1 and IgG4 subtypes reveals the complexity of protein
stability in solution. The three testing methods used, DSC,
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accelerated stability at 40◦C, and stability to solid–liquid inter-
faces, all provided different rankings of stability, inferring dif-
fering mechanisms of damage predominant in each. The shear
device provides an orthogonal approach that can be used as
part of an overall screening process for protein stability. This
provides the basis to characterize the critical routes of degra-
dation encountered during therapeutic protein processing and
storage. The shear device gives relative stability for routes in-
volving shear and solid–liquid interfaces, which are present in
many different steps of protein purification and in transport
and storage of drug product.
The correlation of the molecular modeling results with the
shear device results not only helps to explain the reason behind
the change in stabilities, but underlines the benefits of using
in silico methods for the evaluation of drug candidates in the
future.54
A broader knowledge of antibody characteristics earlier in
the drug lifecycle would allow candidates to be selected for
stability through the primary recovery and downstream pro-
cessing stages of production and will allow better analysis of
long-term storage stability. Increased stability is however not
an indicator for increased product efficacy, another factor that
should be considered.
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